Venetoclax is considered a breakthrough treatment for acute myeloid leukemia (AML). But venetoclax combination therapies do not seem to be as useful for treating acute myeloid leukemia that develops as a complication of myeloproliferative neoplasms, a condition known as post-MPN-AML, according to a study recently published in Blood Advances. Post-MPN-AML is...
Latest News
Among patients with previously treated Waldenström macroglobulinemia (WM), venetoclax appears to be both safe and effective regardless of CXCR4 status, according to research published in the Journal of Clinical Oncology. WM, in which MYD88 and CXCR4 mutations are common, is defined by immunoglobin M secretion in major organs, including the...
San Diego, California – The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in...
Encinitas, Calif. — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, announced financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent pipeline...
BOSTON – AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced results from a randomized confirmatory Phase 2 study of ficlatuzumab as a single agent or in combination with cetuximab (ERBITUX®), an EGFR-targeted antibody, in patients who relapsed or were refractory to prior immunotherapy, chemotherapy,...
MUNICH, Germany — VeonGen Therapeutics, a clinical-stage genetic medicine company developing next-generation gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to VG801, its lead investigational gene therapy for Stargardt disease and other ABCA4 mutation–associated retinal dystrophies. By delivering a...
BRISBANE, Calif. — Vera Therapeutics, Inc., a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In...
BRISBANE, Calif. — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy (IgAN) were presented as a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2025 and simultaneously published in...
SOUTH SAN FRANCISCO, Calif. – Veracyte, Inc. (Nasdaq: VCYT) announced that data reinforcing the diagnostic performance and utility of the Envisia® Genomic Classifier are being shared at the American Thoracic Society (ATS) 2021 International Conference, taking place today through May 18. The company is also presenting new data which demonstrate that the...
BOSTON, Mass. — Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of...